DirectX

Perimeter Medical Imaging AI Announces Webinar Featuring AI Expert, Anantha Kancherla, Discussing Trends in the Use of Machine Learning and Artificial Intelligence in Healthcare Applications

Retrieved on: 
Tuesday, April 16, 2024

With this in mind, Perimeter has built world-class leadership on its Board, the management team, and the engineering department.

Key Points: 
  • With this in mind, Perimeter has built world-class leadership on its Board, the management team, and the engineering department.
  • This webinar showcases the depth of Perimeter's knowledge to apply machine learning models and artificial intelligence tools to our pipeline of products – both existing and still in development.
  • Title: Trends in Artificial Intelligence (AI) and Innovators in Healthcare: Fireside Chat with Perimeter Medical Imaging AI
    Anantha Kancherla is vice president of advanced driver-assistance systems at GM Motors.
  • Prior to Meta, as VP of Engineering at Lyft, Anantha led the Level5 software team responsible for building the self-driving car.

Beckman Coulter's DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

Retrieved on: 
Tuesday, April 16, 2024

Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.

Key Points: 
  • Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.
  • Detection of the viral surface antigen (HBsAg) in serum or plasma indicates an infection caused by hepatitis B virus (HBV).
  • Building on the strengths and global success of the DxI 9000 Analyzer, Beckman Coulter is elevating efficiency and confidence for hepatitis testing.
  • According to Kathleen Orland, Senior Vice President, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics, "By launching these new hepatitis assays on our DxI 9000 Analyzer, we can deliver exceptional quality.

ADLINK reveals new graphics card with Intel Arc A380E GPU at Embedded World 2024

Retrieved on: 
Wednesday, April 10, 2024

SAN JOSE, Calif., April 10, 2024 /PRNewswire-PRWeb/ --

Key Points: 
  • The ADLINK designed EGX-PCIE-A380E incorporates an Intel Arc GPU to deliver a PCIe Gen4 powerful, highly efficient discrete graphics card.
  • ADLINK debuts its first graphics card based on Intel GPU, the A380E, featuring great performance and compatibility with ADLINK gaming platforms.
  • Catch a glimpse of the A380E in action at both ADLINK and Intel booths during Embedded World 2024, where its cutting-edge capabilities will be showcased to enthusiasts and professionals alike.
  • The A380E is a welcome addition to ADLINK's extensive range of A350E/A370E MXM GPU solutions featuring powerful Intel Arc discrete graphics.

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics.
  • These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer.
  • Kevin O’Reilly, President, Beckman Coulter Diagnostics, commented, “We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream.”
    “Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024

BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer's disease therapeutics.
  • Kevin O'Reilly, President, Beckman Coulter Diagnostics, commented, "We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream."
  • "Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world," stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. "We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide."

First patch of "Operation Medic Bag" out now with first improvements and features : Starbreeze AB

Retrieved on: 
Friday, March 1, 2024

STOCKHOLM, March 1, 2024 /PRNewswire/ -- "Operation Medic Bag" is a focused effort to respond to community expectations and improve PAYDAY 3.

Key Points: 
  • STOCKHOLM, March 1, 2024 /PRNewswire/ -- "Operation Medic Bag" is a focused effort to respond to community expectations and improve PAYDAY 3.
  • The initiative covers a range of sought-after features and improvements to gameplay, stability, matchmaking, content and enhanced features.
  • The first patch of "Operation Medic Bag" includes focus initiatives such as rotating stealth modifiers, unready button and improved controller settings.
  • Updates under the "Operation Medic Bag" umbrella are scheduled to increase in cadence, releasing smaller updates more frequently over time.

Acer Expands Gaming Portfolio with New Predator BiFrost and Nitro Series Graphics Cards

Retrieved on: 
Monday, January 8, 2024

LAS VEGAS, Jan. 8, 2024 /PRNewswire/ -- Acer today announced the Predator BiFrost AMD Radeon™ RX 7800 XT OC and a trio of Nitro graphic cards powered by the latest AMD Radeon RX 7000 series GPUs, including the new AMD Radeon RX 7600 XT GPUs. The new graphics cards empower users to experience immersive gaming experiences when playing the latest AAA titles with up to 16GB memory and next-gen technologies.

Key Points: 
  • Acer's latest desktop graphics cards push the boundaries of gaming and creative workflows.
  • The Predator BiFrost AMD Radeon RX 7800 XT OC graphics card fuses the prowess of the AMD RDNA 3 chiplet design and Acer's latest technology advancements.
  • The Acer Nitro AMD Radeon RX 7800 XT OC and Nitro AMD Radeon RX 7700 XT OC graphics cards are primed to present the latest games in their full visual splendor.
  • The Acer Nitro AMD Radeon RX 7600 XT OC graphics card incorporates cutting-edge features for reliable performance.

Imagination Launches Brand New Line of High-performance GPU IP with DirectX

Retrieved on: 
Tuesday, November 7, 2023

Imagination Technologies launches IMG DXD, the first product in a new line of high-performance GPU IP with support for DirectX®*.

Key Points: 
  • Imagination Technologies launches IMG DXD, the first product in a new line of high-performance GPU IP with support for DirectX®*.
  • Products based on Imagination IP are used by billions of people across the globe in their smartphones, cars, homes, and workplaces.
  • Imagination, PowerVR, and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries.
  • *IMG DXD is a GPU IP based on the published DirectX and Khronos API specifications.

CodeWeavers Announces Release of CrossOver 23.5

Retrieved on: 
Wednesday, September 27, 2023

CodeWeavers , the software development company behind CrossOver, today announced its release of CrossOver 23.5 for macOS, Linux, and ChromeOS.

Key Points: 
  • CodeWeavers , the software development company behind CrossOver, today announced its release of CrossOver 23.5 for macOS, Linux, and ChromeOS.
  • CrossOver 23.5 offers Mac gamers significantly improved and simplified gameplay access to the most Windows games on Mac in CodeWeavers’ company history!
  • This release offers an alternate way to run DirectX 11 and DirectX 12 games through CrossOver using its toolkit components.
  • CrossOver 23.5 is the first CrossOver release with support for macOS Sonoma with optimizations from thorough compatibility testing.

First HP Work Relationship Index Shows Majority of People Worldwide Have an Unhealthy Relationship with Work

Retrieved on: 
Wednesday, September 20, 2023

PALO ALTO, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today unveiled groundbreaking findings from its first HP Work Relationship Index, a comprehensive study that explores employees’ relationships with work around the world.* The study, which surveyed more than 15,600 respondents across various industries in 12 countries, reveals the world’s relationship with work is at a breaking point – and its effects are pervasive.

Key Points: 
  • Through this, HP developed its Work Relationship Index, which is a measure of the world’s relationship with work to be tracked over time.
  • The findings spotlight the negative impacts an unhealthy relationship with work has on an employee’s life and an employer’s business.
  • The Work Relationship Index shows that this is a pivotal time to redefine the world’s relationships with work.
  • For more information on the Work Relationship Index, please visit the WRI Website and to access the full report, please visit the HP Newsroom .